Login to Your Account



BIO Convention 2010

Nix 'Lemon-Scent' Knock-offs, Cash Goes to Disruptors: J&J

By Randy Osborne


Monday, May 10, 2010
CHICAGO - A decade ago, pharma firms maintained "an aloof attitude" toward struggling biotechs, condescending to make deals only when the aims of the deep-pocketed savior meshed clearly and perfectly with an early stage innovator, noted Steve Kuemmerle, director of Abbott Biotech Ventures. "Now, we all kind of think we're in the same boat," he said.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription